86 studies found for:    coronado
Show Display Options
Rank Status Study
1 Not yet recruiting TSO for Plaque Psoriasis
Condition: Plaque Psoriasis
Intervention: Biological: Trichuris Suis Ova
2 Recruiting Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure
Condition: Acute Alcoholic Hepatitis
Interventions: Biological: ELAD  treatment;   Other: Standard of care (Control)
3 Active, not recruiting Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Condition: Crohn's Disease
Interventions: Biological: Trichuris suis ova (TSO);   Biological: Placebo
4 Active, not recruiting Trichuris Suis Ova in Autism Spectrum Disorders
Condition: Autism
Intervention: Drug: Trichuris Suis Ova
5 Completed
Has Results
Safety and Tolerability of Single Doses Oral CNDO 201 Trichuris Suis Ova in Patients With Crohn's Disease
Condition: Crohn's Disease
Interventions: Biological: Trichuris suis ova;   Other: Placebo
6 Recruiting Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo in Autism Spectrum Disorder
Condition: Autism
Interventions: Biological: Trichuris suis ova;   Other: Placebo
7 Recruiting CNDO-109-AANK for AML in First Complete Remission (CR1)
Condition: Acute Myeloid Leukemia
Intervention: Biological: CNDO-109-AANK Cells
8 Active, not recruiting A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
Condition: Chronic Hepatitis C Infection
Interventions: Drug: ABT-450/r/ABT-267;   Drug: ABT-333;   Drug: Ribavirin;   Drug: Placebo for Ribavirin
9 Completed
Has Results
An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients
Condition: Hepatitis C
Interventions: Drug: Placebo;   Drug: TMC435;   Drug: Peginterferon alpha-2a (PegIFN alpha-2a);   Drug: Ribavirin (RBV)
10 Enrolling by invitation A Follow up Study Designed to Obtain Long Term Data on Subjects Who Either Achieved a Sustained Virologic Response or or Did Not Achieve a Sustained Virologic Response in an Abbott Sponsored Hepatitis C Study
Condition: Hepatitis C
Interventions: Drug: ABT-450/ritonavir;   Drug: ABT-333;   Drug: ABT-267
11 Completed Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)
Condition: Hepatitis C
Interventions: Drug: BI201335;   Drug: PegIFN/RBV
12 Completed Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects
Condition: Hepatitis C, Chronic
Interventions: Drug: GSK2336805;   Drug: Pegylated interferon alfa-2a;   Drug: Ribavirin;   Drug: GSK2336805 Matching Placebo
13 Completed
Has Results
VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo
Condition: Hepatitis C, Chronic
Interventions: Drug: Telaprevir;   Drug: pegylated interferon (Peg-IFN) alfa-2a;   Drug: ribavirin (RBV)
14 Enrolling by invitation A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Condition: Hepatitis C, Chronic
Intervention:
15 Recruiting A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
Condition: Ulcerative Colitis
Intervention:
16 Enrolling by invitation Gilead Sustained Virologic Response (SVR) Registry
Condition: Hepatitis C, Chronic
Intervention:
17 Active, not recruiting A Study to Evaluate the Safety and Effect of ABT-450, Ritonavir and ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis
Conditions: Chronic Hepatitis C;   Compensated Cirrhosis;   Hepatitis C Virus
Interventions: Drug: ABT-450/r/ABT-267;   Drug: ABT-333;   Drug: Ribavirin (RBV)
18 Completed A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Condition: Hepatorenal Syndrome Type 1
Interventions: Drug: Terlipressin;   Drug: Placebo
19 Unknown  Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection
Condition: Hepatitis C, Chronic
Interventions: Drug: PEG-rIL-29;   Drug: Peginterferon alfa-2a;   Drug: Ribavirin
20 Active, not recruiting Simtuzumab (GS-6624) in the Treatment of Cirrhosis Due to NASH
Condition: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Biological: Simtuzumab;   Biological: Placebo

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years